Working... Menu

Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00717756
Recruitment Status : Completed
First Posted : July 17, 2008
Results First Posted : April 3, 2014
Last Update Posted : April 25, 2019
Memorial Hospital of Rhode Island
Roger Williams Medical Center
Information provided by (Responsible Party):
howard safran, Brown University

Brief Summary:
This study will determine whether lenalidomide has activity in patients with advanced liver cancer that have had growth of their cancer after sorafenib.

Condition or disease Intervention/treatment Phase
Liver Cancer Drug: lenalidomide Phase 2

Detailed Description:
This study will determine the response rate and toxicities of lenalidomide as second line treatment for patients with liver cancer who have progressed after sorafenib.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 41 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial
Study Start Date : January 2009
Actual Primary Completion Date : December 2013
Actual Study Completion Date : January 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Liver Cancer

Arm Intervention/treatment
Experimental: Lenalidomide Drug: lenalidomide
25 mg po qd x 21 days then 1 week off equals one cycle
Other Name: revlimid

Primary Outcome Measures :
  1. Response Rate by Recist Criteria [ Time Frame: on average about every 2 months until progression, on average about 4 months. ]

    radiographic response defined as partial response defined by RECIST:At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD

    It is noted that while on average the time frame for scans was 4 months, there were two patients who at 32 and 36 months had not progressed.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Pathologically confirmed HCC or triple phase CT consistent with HCC in a patient with known cirrhosis and AFP > 200 ng/ml.
  2. Disease not amenable to curative surgical resection
  3. Patients must have been previously treated with sorafenib. Patients who are unable to receive sorafenib due to financial reasons are also eligible.
  4. All previous cancer therapy, including radiation, hormonal therapy and surgery, must have been discontinued at least 4 weeks prior to treatment in this study.
  5. No previous thalidomide.
  6. Patients must have radiologically assessable tumor.
  7. ECOG performance status of 0-2 at study entry.
  8. Understand and voluntarily sign an informed consent form.
  9. Age >18 years at the time of signing the informed consent form.
  10. Able to adhere to the study visit schedule and other protocol requirements.
  11. Laboratory test results within these ranges:

    • Absolute neutrophil count > 1000/mm3
    • Platelet count > 60,000/mm3
    • Serum creatinine > 2.0 mg/dL
    • Total bilirubin > 4 mg/dL
    • AST (SGOT) and ALT (SGPT) > 5 x ULN.
  12. Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure. See Appendix: H Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control Methods, AND also Appendix: F Education and Counseling Guidance Document
  13. Disease free of prior malignancies for > 2 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "insitu" of the cervix or breast

Exclusion Criteria:

  1. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
  2. Pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking lenalidomide).
  3. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
  4. Use of any other experimental drug or therapy within 28 days of baseline.
  5. Known hypersensitivity to thalidomide.
  6. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
  7. Any prior use of lenalidomide.
  8. Concurrent use of other anti-cancer agents or treatments.
  9. Known positive for HIV. (The effect of immune modulation of lenalidomide on patients who are HIV positive is unknown).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00717756

Layout table for location information
United States, New York
Montefiore Medical Center
Bronx, New York, United States, 10467
United States, Rhode Island
Memorial Hospital of Rhode island
Pawtucket, Rhode Island, United States, 02860
Lifespan Hospitals
Providence, Rhode Island, United States, 02903
Sponsors and Collaborators
Brown University
Memorial Hospital of Rhode Island
Roger Williams Medical Center
Layout table for investigator information
Principal Investigator: Howard Safran, MD Brown University

Publications of Results:
Layout table for additonal information
Responsible Party: howard safran, Principle Investigator, Brown University Identifier: NCT00717756     History of Changes
Other Study ID Numbers: BrUOG-HC-212
Celgene # RV-HCC-PI- 0159 ( Other Identifier: brown university )
celgene ( Other Identifier: brown university )
First Posted: July 17, 2008    Key Record Dates
Results First Posted: April 3, 2014
Last Update Posted: April 25, 2019
Last Verified: April 2019

Keywords provided by howard safran, Brown University:
liver cancer, second line

Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Neoplasms
Carcinoma, Hepatocellular
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents